- A randomized Phase II study of Irinotecan and
Cetuximab with or without the anti-angiogenic
antibody, Ramucirumab, in advanced K-ras
wild-type colorectal cancer following
progression on Bevacizumab-containing
TYPE OF CANCER? WHAT STAGE?
Colorectal cancer, unrectable, recurrent, or
Patients who are k-Ras wild-type and already
failed chemotherapy with Bevacizumab (Avastin).
WILL I BE TREATED?
Patients will be treated with Irinotecan +
Cetuximab and will be randomized to Ramucirumab
(an anti-angiogenic antibody).
Send an Inquiry
This website is only for the purpose of sending
an inquiry about a clinical trial. Your contact information will be passed
our clinical trial coordinators who will pass on your contact information to
the physician’s office that is sponsoring the trial that you are interested
in. Entry into any clinical trial is not guaranteed – reasons for this
include but are not limited to the fact that you may not be eligible, the
trial may be completed or closed, or the possible treatments may not be
indicated or appropriate for you.
We will attempt to contact you via your inquiry
within (5) five business days, however, we cannot guarantee that you will be
contacted. Though we update this website several times a year, there may be
clinical trials that are not on this list or trials on this list may have
This website does not is not designed to give
medical advice, and does not take the place of your physician. If you have
an urgent medical matter, please contact your physician or call emergency
Padmanabha, M.D., and Jefferson Radiation Oncology, 2018.